← Back to patent-cliff list
VK-2735
Tier C — Watch / tradeVK-2735
Viking Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GLP1R, GIPR
Indications (approved)：Obesity, 体重减轻, Non-alcoholic steatohepatitis
Regional status
US
Phase III
2025-06-23
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of VK-2735?
Approved indications include: Obesity, 体重减轻, Non-alcoholic steatohepatitis.
When does the VK-2735 patent expire?
No public expiry year is available for VK-2735 yet; this page updates once verified.
How do I get a quote for VK-2735 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30